Assignee
UCB Biopharma SRL
BE·95 granted patents·97 pending applications·81 citations·filing 2015–2025
Top patents by PatentIndex Score
192 records- 0196US10705094B2TNF receptor signaling modulator assayUCB Biopharma SRL·Filed 2015·Granted Jul 7, 2020·9 cites·18 claims
- 0295US10883996B2Methods of identifying signaling modulators of the trimeric TNFaUCB Biopharma SRL·Filed 2015·Granted Jan 5, 2021·7 cites·5 claims
- 0393US11448655B2Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptorsUCB Biopharma SRL·Filed 2020·Granted Sep 20, 2022·2 cites·17 claims
- 0493US11022614B2Antibodies binding to trimeric TNF alpha epitopesUCB Biopharma SRL·Filed 2015·Granted Jun 1, 2021·5 cites·17 claims
- 0593US10969393B2Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding themUCB Biopharma SRL·Filed 2015·Granted Apr 6, 2021·5 cites·11 claims
- 0692US11807680B2Gremlin-1 crystal structure and inhibitory antibodyUCB Biopharma SRL·Filed 2021·Granted Nov 7, 2023·3 cites·4 claims
- 0792US11674967B2Method of identifying potential inhibitors of APO TNFα trimersUCB Biopharma SRL·Filed 2020·Granted Jun 13, 2023·2 cites·19 claims
- 0891US11472879B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2020·Granted Oct 18, 2022·2 cites·20 claims
- 0989US10954312B2Method employing bispecific protein complexUCB Biopharma SRL·Filed 2016·Granted Mar 23, 2021·5 cites·16 claims
- 1089US10947304B2Gremlin-1 antibodyUCB Biopharma SRL·Filed 2017·Granted Mar 16, 2021·6 cites·12 claims
- 1189US2025012807A1Mechanism of actionUCB Biopharma SRL·Filed 2024·Application pending·0 cites
- 1288US12055549B2Methods of use of anti-TNFα antibodiesUCB Biopharma SRL·Filed 2021·Granted Aug 6, 2024·1 cites·16 claims
- 1388US11261242B2Anti-alpha-synuclein antibodiesUCB Biopharma SRL·Filed 2018·Granted Mar 1, 2022·3 cites·21 claims
- 1488USRE48787EHumanised antibodiesUCB Biopharma SRL·Filed 2019·Granted Oct 26, 2021·2 cites·19 claims
- 1588US2024376191A1Antibody molecules which bind il-17a and il-17fUCB Biopharma SRL·Filed 2024·Application pending·0 cites
- 1687US11524997B2Gremlin-1 inhibitor for the treatment of a bone fracture or bone defectUCB Biopharma SRL·Filed 2019·Granted Dec 13, 2022·4 cites·12 claims
- 1787US11261252B2Molecules with specificity for CD79 and CD22UCB Biopharma SRL·Filed 2019·Granted Mar 1, 2022·2 cites·10 claims
- 1886US11174311B2Antibody against trimeric TNFα complexUCB Biopharma SRL·Filed 2017·Granted Nov 16, 2021·4 cites·14 claims
- 1985US12474348B2Complexes between CD40 and compounds comprising benzimidazole moietiesUCB Biopharma SRL·Filed 2022·Granted Nov 18, 2025·0 cites·6 claims
- 2085US11312716B29H-pyrrolo-dipyridine derivativesUCB Biopharma SRL·Filed 2020·Granted Apr 26, 2022·2 cites·4 claims
- 2185US10906919B2Fused pentacyclic imidazole derivativesUCB Biopharma SRL·Filed 2018·Granted Feb 2, 2021·2 cites·10 claims
- 2283US10906966B2Tau-binding antibodiesUCB Biopharma SRL·Filed 2019·Granted Feb 2, 2021·1 cites·19 claims
- 2383US2025346672A1Anti-fcrn antibodiesUCB Biopharma SRL·Filed 2025·Application pending·0 cites
- 2482US12473355B2Gremlin-1 crystal structure and inhibitory antibodyUCB Biopharma SRL·Filed 2023·Granted Nov 18, 2025·0 cites·17 claims
- 2582USRE50178EHumanised antibodiesUCB Biopharma SRL·Filed 2021·Granted Oct 22, 2024·0 cites·20 claims
- 2680US12338285B2Anti-FcRn antibodiesUCB Biopharma SRL·Filed 2022·Granted Jun 24, 2025·0 cites·52 claims
- 2780US2023331833A1Tau-binding antibodiesUCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 2880US2023135399A1Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereofUCB Biopharma SRL·Filed 2022·Application pending·0 cites
- 2980US2025127795A1Fused Pentacyclic Imidazole Derivatives as Modulators of TNF ActivityUCB Biopharma SRL·Filed 2024·Application pending·0 cites
- 3079US12331117B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2022·Granted Jun 17, 2025·0 cites·20 claims
- 3179US11857625B2Pharmaceutical compositionsUCB Biopharma SRL·Filed 2018·Granted Jan 2, 2024·2 cites·9 claims
- 3279US2023250105A1Fused Pentacyclic Imidazole Derivatives as Modulators of TNF ActivityUCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 3378US11919950B2Expression vector encoding antibody molecule which binds IL-17A and IL-17FUCB Biopharma SRL·Filed 2020·Granted Mar 5, 2024·0 cites·8 claims
- 3478US2023416350A1Tau-binding antibodiesUCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 3577US11142794B2Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseasesUCB Biopharma SRL·Filed 2016·Granted Oct 12, 2021·3 cites·18 claims
- 3677US2021140972A1Mechanism of actionUCB Biopharma SRL·Filed 2020·Application pending·0 cites
- 3777US2021132079A1AntibodyUCB Biopharma SRL·Filed 2021·Application pending·0 cites
- 3876US2025011473A1ANTI-IgE ANTIBODIESUCB Biopharma SRL·Filed 2024·Application pending·0 cites
- 3976US2024352083A1Antibodies comprising a polypeptide inserted in framework 3 regionUCB Biopharma SRL·Filed 2024·Application pending·0 cites
- 4076US2025270308A1Antibody epitopeUCB Biopharma SRL·Filed 2025·Application pending·0 cites
- 4175US12275777B2Process for obtaining antibodiesUCB Biopharma SRL·Filed 2022·Granted Apr 15, 2025·0 cites·13 claims
- 4274US11292831B2Anti-alpha synuclein antibodiesUCB Biopharma SRL·Filed 2018·Granted Apr 5, 2022·1 cites·21 claims
- 4374US11261470B2Recombinant bacterial host cell for protein expressionUCB Biopharma SRL·Filed 2018·Granted Mar 1, 2022·1 cites·20 claims
- 4473US12428497B2Multispecific antibody constructsUCB Biopharma SRL·Filed 2022·Granted Sep 30, 2025·0 cites·23 claims
- 4573US11746145B2Tau-binding antibodiesUCB Biopharma SRL·Filed 2020·Granted Sep 5, 2023·0 cites·18 claims
- 4672US12240896B2Gremlin-1 inhibitor for the treatment of a bone fracture or bone defectUCB Biopharma SRL·Filed 2022·Granted Mar 4, 2025·0 cites·4 claims
- 4772US11155566B22-OXO-1-pyrrolidinyl imidazothiadiazole derivativesUCB Biopharma SRL·Filed 2018·Granted Oct 26, 2021·1 cites·11 claims
- 4871US12077796B2Cell culture methodsUCB Biopharma SRL·Filed 2018·Granted Sep 3, 2024·1 cites·20 claims
- 4971US12054559B2Anti-IgE antibodiesUCB Biopharma SRL·Filed 2021·Granted Aug 6, 2024·0 cites·12 claims
- 5071US11975046B2Medical use of interferon-lambda for the treatment of fibrosisUCB Biopharma SRL·Filed 2023·Granted May 7, 2024·0 cites·10 claims
Showing the top 50 of 192 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when UCB Biopharma SRL files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →